Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.

Efrat T Harel Jun Shoji Vivek Abraham Loan Miller Zoltan G Laszik Tine Thurison Andrew J King Adam B Olshen Joey Leung Gyula Szabo Byron C Hann Gunilla Høyer-Hansen Charles S Craik Flavio G Vincenti

Published in: Clinical transplantation (2019)

Our analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR-FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.

Keyphrases

high throughput
cell therapy
case control
bone marrow
monoclonal antibody